Therefore, nanocarrier conjugation with the DR5-selective cytokine DR5-B allows for the avoidance of this obstacle with the advantage of overcoming the receptor-dependent resistance of tumor cells to TRAIL. Here, TNFRSF10B is linked to neoplasm.